Evidence map›Paper›PMID 34093572›Full record

ArticleFrontiers in immunology2021

TLR9- and CD40-Targeting Vaccination Promotes Human B Cell Maturation and IgG Induction

Liang Cheng, Guangming Li, Caroline Marnata Pellegry, Fumihiko Yasui, Feng Li, Sandra M Zurawski, Gerard Zurawski, Yves Levy, Jenny P-Y Ting, Lishan Su

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Liang ChengLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Guangming LiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Caroline Marnata PellegryLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Fumihiko YasuiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Feng LiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Sandra M ZurawskiBaylor Institute for Immunology Research, Vaccine Research Institute, INSERM U955, Dallas, TX, United States.
Gerard ZurawskiBaylor Institute for Immunology Research, Vaccine Research Institute, INSERM U955, Dallas, TX, United States.
Yves LevyAssistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France.
Jenny P-Y TingLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Lishan SuLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill · USGuangzhou Eighth People's Hospital · CNHôpital Albert-Chenevier · FRWuhan University · CN

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirsR01AI136990 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMARA, RAMA RAO, BOSINGER, STEVEN EDWARD · 2018 to 2022
$4.2M
NCI NIH HHS P30 CA016086NIAID NIH HHS R01 AI136990
6 · The paper itself

Abstract

Mice reconstituted with a human immune system (humanized mice) provide a robust model to study human immunology, vaccinology, and human infectious diseases. However, the development and function of B cells in humanized mice is impaired. B cells from humanized mice are immature and are impaired in IgM to IgG isotype switch in response to infection or vaccination. In the present study we report that Toll-like receptor 9 (TLR9) agonist CpG-B combined with CD40-targeting vaccination triggered human B cell immunoglobin class-switch from IgM

Indexed as

Adjuvants, ImmunologicAnimalsB-LymphocytesCD40 AntigensDendritic CellsHIV-1HumansImmunoglobulin Class SwitchingImmunoglobulin GMiceOligodeoxyribonucleotidesToll-Like Receptor 9VaccinationAdjuvants, ImmunologicCD40 AntigensImmunoglobulin GOligodeoxyribonucleotidesToll-Like Receptor 9B cell maturationCD40-targeting vaccinationCpG-BIFN-alphaIgG inductionimmunoglobin class-switchplasmacytoid dendritic cell

Identifiers

PMID34093572
PMCPMC8169971
OpenAlexW3160664551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.